Group 1 - The company announced a conditional agreement to acquire 100% of the issued share capital and loans of the target company, Aono Hong Kong, for a total consideration of HKD 22 million, which will result in the target company becoming an indirect wholly-owned subsidiary [1] - Following the acquisition, the company will hold a 37.5% equity interest in Beisheng Biotechnology, and the financial performance, assets, and liabilities of Beisheng will be accounted for using the equity method in the company's financial statements [1] - Beisheng Biotechnology specializes in strain design and fermentation process development, providing high-quality, convenient, and cost-effective technical services and related products for synthetic biology enterprises and traditional fermentation companies seeking to upgrade through synthetic biology technology [1][2] Group 2 - The company believes that the research and development of proprietary rights and technologies related to healthcare and beauty businesses is key to gaining a competitive advantage [2] - Current R&D focuses include a dual-protein water light needle using hyaluronic acid penetration enhancement technology, composite fillers targeting the temporal filler market, photo-activated collagen repair essence, and targeted anti-aging therapies using stem cell exosomes [2] - The acquisition of Beisheng Biotechnology is expected to enhance the efficiency of the company's R&D projects, reduce R&D costs, and accelerate the commercialization of R&D results [3]
朸濬国际(01355)拟收购奥诺香港已发行股本的100%